论文部分内容阅读
目的:探讨米非司酮配伍米索前列醇行药物流产安全性。方法:选取我站于2011年6月-2014年6月期间100例孕妇作为研究对象,将其随机分为实验组和对照组,每组各50例,对照组孕妇给予米非司酮进行治疗,实验组孕妇采用米非司酮配伍米索前列醇进行治疗,对两组孕妇的流产情况、流产后的出血量和流产后的出血时间进行对比。结果:实验组孕妇的安全流产率明显高于对照组孕妇,且出血量明显少于对照组孕妇,出血时间比对照组孕妇出血时间短,该差异具有统计学意义(P<0.05)。结论:米非司酮配伍米索前列醇可有效提高安全流产率,减少流产后的出血时间及出血量,具有安全性,值得在临床推广应用。
Objective: To investigate the safety of mifepristone and misoprostol in medical abortion. Methods: From June 2011 to June 2014, 100 pregnant women were selected as study subjects and randomly divided into experimental group and control group, with 50 cases in each group. The pregnant women in the control group were treated with mifepristone The pregnant women in the experimental group were treated with mifepristone and misoprostol. The abortion status, the amount of bleeding after abortion and the bleeding time after abortion were compared. Results: The safe abortion rate of pregnant women in experimental group was significantly higher than that of pregnant women in control group, and the bleeding volume was significantly less than that of pregnant women in control group. The bleeding time was shorter than that of pregnant women in control group (P <0.05). Conclusion: Mifepristone combined with misoprostol can effectively improve the safety of abortion rate and reduce the bleeding time and bleeding after abortion, which is safe and worthy of clinical application.